title: [Resolution of inflammation--pharmacological aspects].
abstract: Inflammation is a fundamental biologic process evolutionally preserved by a germ line code. The interplay of the epigenetic with the environment directs the code to temporally distinct inflammatory responses, which can be acute or chronic. The aim of this study is to present new aspects regarding the resolution of inflammation. Acute inflammation normally resolves by mechanisms still somewhat elusive. Current evidence suggests that an active coordinated program initiated the first few hours after the inflammatory response begins and its failure lead to chronic inflammation. This process is essential for appropriate host responses, tissue protection and the return to homeostasis. Prostaglandins and leukotrienes are lipid mediators that play important roles in host defense and acute inflammation. Granulocytes promote the switch of arachidonic acid-derived prostaglandins and leukotrienes to lipoxins, active antiinflammatory and pro-resolution mediators. The apoptosis of the neutrophils coincides with the biosynthesis of resolvins and protectins from omega-3 polyunsaturated fatty acids and releases anti-inflammatory and reparative cytokines. This information could lead to new treatments for inflammatory diseases.
authors.affiliation: Universitatea de Medicină şi Farmacie Gr. T. Popa Iaşi Facultatea de Medicină, Disciplina de Semiologie generală.
authors.forename: Maria M
authors.initials: MM
authors.lastname: Leon
authors.forename: Irina M
authors.initials: IM
authors.lastname: Jaba
authors.forename: Corina Dima
authors.initials: CD
authors.lastname: Cozma
authors.forename: Elena
authors.initials: E
authors.lastname: Albu
authors.forename: Roxana
authors.initials: R
authors.lastname: Bahnea
authors.forename: O C
authors.initials: OC
authors.lastname: Mungiu
mesh_terms: D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018957:CD59 Antigens / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D004281:Docosahexaenoic Acids / Q000494:pharmacology / Q000627:therapeutic use; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism / Q000517:prevention & control; D018836:Inflammation Mediators / Q000276:immunology*; D044045:Lipoxins / Q000494:pharmacology / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D018957:CD59 Antigens; D005938:Glucocorticoids; D018836:Inflammation Mediators; D044045:Lipoxins; C518399:resolvin D1; D004281:Docosahexaenoic Acids; D013482:Superoxide Dismutase